Management of diabetes mellitus in individuals with chronic kidney disease: Therapeutic perspectives and glycemic control

Clinics

Volumn 71, Issue 1, 2016, Pages 47-53

  Betônico, Carolina C R ^a   Titan, Silvia M O ^b   Correa Giannella, Maria Lúcia C ^c   Nery, Márcia ^d   Queiroz, Márcia ^d  

^a Universidade Oeste Paulista   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Laboratório de Endocrinologia Celular e Molecular LIM 25   (Brazil)

^d Medicina Preventiva   (Brazil)

Author keywords

Chronic kidney disease; Diabetes treatment; Diabetic kidney disease; Oral antidiabetic drugs; Renal failure; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; CREATININE; GLUCOSE BLOOD LEVEL;

COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE COURSE; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; PATIENT COMPLIANCE; RENAL INSUFFICIENCY, CHRONIC;

BLOOD GLUCOSE; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT COMPLIANCE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84957606504     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2016(01)08     Document Type: Review

References (70)

1. Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control,complications, and death in older diabetic patients: the diabetes andaging study. Diabetes Care. 2011;34(6):1329-36, http://dx.doi.org/10.2337/dc10-2377.
2. Grandfils N, Detournay B, Attali C, Joly D, Simon D, Vergès B, et al.Glucose lowering therapeutic strategies for type 2 diabetic patients withchronic kidney disease in primary care setting in france: a cross-sectionalstudy. Int J Endocrinol. 2013;2013:640632, http://dx.doi.org/10.1155/2013/640632.
3. Hager SR. Insulin resistance of uremia. Am J Kidney Dis. 1989;14(4):272-6,http://dx.doi.org/10.1016/S0272-6386(89)80201-X.
4. Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E,et al. Insulin resistance and hyperinsulinemia are already present inpatients with incipient renal disease. Kidney Int. 1998;53(5):1343-7, http://dx.doi.org/10.1046/j.1523-1755.1998.00898.x.
5. Smith D, DeFronzo RA. Insulin resistance in uremia mediated by postbindingdefects. Kidney Int. 1982;22(1):54-62, http://dx.doi.org/10.1038/ki.1982.132.
6. Fioretto P, Bruseghin M, Berto I, Gallina P, Manzato E, Mussap M. Renalprotection in diabetes: role of glycemic control. J Am Soc Nephrol. 2006;17(4 Suppl 2):S86-9, http://dx.doi.org/10.1681/ASN.2005121343.
7. Foundation NK. KDOQI Clinical Practice Guideline for Diabetes andCKD: 2012 Update. Am J Kidney Dis. Elsevier Inc. 2012;60(5):850-86.
8. Classification I, Classification A. Standards of medical care in diabetes--2014. Diabetes Care. 2014;37 Suppl 1:S14-80, http://dx.doi.org/10.2337/dc14-S014.
9. Game F. Novel hypoglycaemic agents: considerations in patients with chronickidney disease. Nephron Clin Pract. 2014;126(1):14-8, http://dx.doi.org/10.1159/000357680.
10. Sibal L, Home PD. Management of type 2 diabetes: NICE guidelines. ClinMed . 2009;9(4):353-7, http://dx.doi.org/10.7861/clinmedicine.9-4-353.
11. Wu N, Yu X, Greene M, Oderda G. Evaluation of the Prevalence ofChronic Kidney Disease and Rates of Oral Antidiabetic Prescribing inAccordance with Guidelines and Manufacturer Recommendations inType 2 Diabetic Patients within a Long-Term Care Setting. Int J Nephrol.2014;2014:151706, http://dx.doi.org/10.1155/2014/151706.
12. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M,et al. Management of hyperglycemia in type 2 diabetes: a patient-centeredapproach: position statement of the American Diabetes Association(ADA) and the European Association for the Study of Diabetes (EASD).Diabetes Care. 2012;35(6):1364-79, http://dx.doi.org/10.2337/dc12-0413.
13. Kajbaf F, Arnouts P, de Broe M, Lalau J-D. Metformin therapy and kidneydisease: a review of guidelines and proposals for metformin withdrawalaround the world. Pharmacoepidemiol Drug Saf. 2013;22(10):1027-35,http://dx.doi.org/10.1002/pds.3501.
14. Penfornis A, Blicklé JF, Fiquet B, Quéré S, Dejager S. How are patientswith type 2 diabetes and renal disease monitored and managed? Insightsfrom the observational OREDIA study. Vasc Health Risk Manag. 2014;10:341-52.
15. Lalau J-D, Arnouts P, Sharif A, De Broe ME. Metformin and other antidiabeticagents in renal failure patients. Kidney Int. 2015;87(2):308-22,http://dx.doi.org/10.1038/ki.2014.19.
16. Meadows T a, Bhatt DL, Cannon CP, Gersh BJ, Röther J, Goto S, et al.Ethnic differences in cardiovascular risks and mortality in atherothromboticdisease: insights from the Reduction of Atherothrombosis forContinued Health (REACH) registry. Mayo Clin Proc. 2011;86(10):960-7,http://dx.doi.org/10.4065/mcp.2011.0010.
17. Roussel R, Travert F, Pasquet B, Wilson PWF, Smith SC, Goto S, et al.Metformin use and mortality among patients with diabetes and atherothrombosis.Arch Intern Med. 2010;170(21):1892-9, http://dx.doi.org/10.1001/archinternmed.2010.409.
18. Kim J, Shon E, Kim C-S, Kim JS. Renal podocyte injury in a rat modelof type 2 diabetes is prevented by metformin. Exp Diabetes Res. 2012;2012:210821, http://dx.doi.org/10.1155/2012/210821.
19. Piwkowska A, Rogacka D, Jankowski M, Dominiczak MH, Stepiński JK,Angielski S. Metformin induces suppression of NAD(P)H oxidase activityin podocytes. Biochem Biophys Res Commun. 2010;393(2):268-73, http://dx.doi.org/10.1016/j.bbrc.2010.01.119.
20. Ha H, Kim C, Son Y, Chung MH, Kim KH. DNA damage in the kidneys ofdiabetic rats exhibiting microalbuminuria. Free Radic Biol Med. 1994;16(2):271-4, http://dx.doi.org/10.1016/0891-5849(94)90152-X.
21. Zanchi A, Lehmann R, Philippe J. Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology.Swiss Med Wkly. 2012;142:w13629, http://dx.doi.org/10.4414/smw.2012.13629.
22. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J,et al. Diabetic Kidney Disease: A Report From an ADA Consensus Conference.Diabetes Care. 2014;37(10):2864-83, http://dx.doi.org/10.2337/dc14-1296.
23. Sampanis C. Management of hyperglycemia in patients with diabetesmellitus and chronic renal failure. Hippokratia. 2008;12(1):22-7.
24. Inoue T, Shibahara N, Miyagawa K, Itahana R, Izumi M, Nakanishi T,et al. Pharmacokinetics of nateglinide and its metabolites in subjects withtype 2 diabetes mellitus and renal failure. Clin Nephrol. 2003;60(2):90-5,http://dx.doi.org/10.5414/CNP60090.
25. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patientswith and without impaired renal function. Diabetes Care. 2003;26(3):886-91,http://dx.doi.org/10.2337/diacare.26.3.886.
26. Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronickidney disease and end-stage renal disease on dialysis: metabolism andclinical practice. Curr Drug Metab. 2011;12(1):57-69, http://dx.doi.org/10.2174/138920011794520053.
27. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patientswith diabetes mellitus and CKD. Am J Kidney Dis. 2007;50(5):865-79,http://dx.doi.org/10.1053/j.ajkd.2007.08.012.
28. Williams ME, Garg R. Glycemic management in ESRD and earlier stagesof CKD. Am J Kidney Dis. 2014;63(2 Suppl 2):S22-38, http://dx.doi.org/10.1053/j.ajkd.2013.10.049.
29. Budde K, Neumayer H-H, Fritsche L, Sulowicz W, Stompôr T, Eckland D.The pharmacokinetics of pioglitazone in patients with impaired renalfunction. Br J Clin Pharmacol. 2003;55(4):368-74, http://dx.doi.org/10.1046/j.1365-2125.2003.01785.x.
30. Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E.Effect of pioglitazone on cardiovascular outcome in diabetes and chronickidney disease. J Am Soc Nephrol. 2008;19(1):182-7, http://dx.doi.org/10.1681/ASN.2007060678.
31. Russo E, Penno G, Del Prato S. Managing diabetic patients with moderateor severe renal impairment using DPP-4 inhibitors: focus on vildagliptin.Diabetes Metab Syndr Obes. 2013;6:161-70.
32. Eligar VS, Bain SC. A review of sitagliptin with special emphasis on its use inmoderate to severe renal impairment. Drug Des Devel Ther. 2013;7:893-903.
33. Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies inpatients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet.2015;54(1):1-21, http://dx.doi.org/10.1007/s40262-014-0198-2.
34. Nowicki M1, Rychlik I, Haller H, Warren ML, Suchower L G-NI. Saxagliptinimproves glycaemic control and is well tolerated in patients withtype 2 diabetes mellitus and renal impairment. Diabetes Obes Metab.2011;13(6):523-32, http://dx.doi.org/10.1111/j.1463-1326.2011.01382.x.
35. von Eynatten M, Gong Y, Emser A, Woerle HJ. Efficacy and safety oflinagliptin in type 2 diabetes subjects at high risk for renal and cardiovasculardisease?: a pooled analysis of six phase III clinical trials. CardiovascDiabetol. 2013;1-9, http://dx.doi.org/10.1186/1475-2840-12-60.
36. Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetesmellitus. Drugs. 2010;70(15):2051-72, http://dx.doi.org/10.2165/11205080-000000000-00000.
37. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P,et al. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations fromthe SAVOR-TIMI 53 Randomized Trial. Circulation. 2014;130(18):1579-88,http://dx.doi.org/10.1161/CIRCULATIONAHA.114.010389.
38. Standl E, Erbach M, Schnell O. Dipeptidyl-peptidase-4 Inhibitors andHeart Failure: Class Effect, Substance-Specific Effect, or Chance Effect?Curr Treat Options Cardiovasc Med. 2014;16(12):353, http://dx.doi.org/10.1007/s11936-014-0353-y.
39. Giorda CB, Nada E, Tartaglino B. Pharmacokinetics, safety, and efficacy ofDPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetesmellitus and renal or hepatic impairment. A systematic reviewof the literature.Endocrine. 2014;46(3):406-19, http://dx.doi.org/10.1007/s12020-014-0179-0.
40. Freeman JS. Review of insulin-dependent and insulin-independent agentsfor treating patients with type 2 diabetes mellitus and potential rolefor sodium-glucose co-transporter 2 inhibitors. Postgrad Med. 2013;125(3):214-26, http://dx.doi.org/10.3810/pgm.2013.05.2672.
41. Yamout H, Perkovic V, Davies M, Woo V, de Zeeuw D, Mayer C, et al.Efficacy and safety of canagliflozin in patients with type 2 diabetes andstage 3 nephropathy. Am J Nephrol. 2014;40(1):64-74, http://dx.doi.org/10.1159/000364909.
42. Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin.Diabetologia. 1984;27(3):351-7, http://dx.doi.org/10.1007/BF00304849.
43. Duckworth WC, Kitabchi AE. Insulin metabolism and degradation.Endocr Rev. 1981 Spring;2(2):210-33, http://dx.doi.org/10.1210/edrv-2-2-210.
44. Duckworth WC. Insulin degradation: mechanisms, products, and significance.Endocr Rev. 1988;9(3):319-45, http://dx.doi.org/10.1210/edrv-9-3-319.
45. Iglesias P, Díez JJ. Insulin therapy in renal disease. Diabetes Obes Metab.2008;10(10):811-23, http://dx.doi.org/10.1111/j.1463-1326.2007.00802.x.
46. Charlesworth JA, Kriketos AD, Jones JE, Erlich JH, Campbell L V, PeakePW. Insulin resistance and postprandial triglyceride levels in primaryrenal disease. Metabolism. 2005;54(6):821-8, http://dx.doi.org/10.1016/j.metabol.2005.01.028.
47. Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G. Decreased insulinrequirement in relation to GFR in nephropathic Type 1 and insulin-treatedType 2 diabetic patients. Diabet Med. 2003;20(8):642-5, http://dx.doi.org/10.1046/j.1464-5491.2003.01025.x.
48. Kulozik F, Hasslacher C. Insulin requirements in patients with diabetesand declining kidney function: differences between insulin analoguesand human insulin? Ther Adv Endocrinol Metab. 2013;4(4):113-21, http://dx.doi.org/10.1177/2042018813501188.
49. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications inpatients with diabetes mellitus and advanced kidney disease. Semin Dial.2004;17(5):365-70, http://dx.doi.org/10.1111/j.0894-0959.2004.17346.x.
50. Gillies PS, Figgitt DP, Lamb HM. Insulin glargine. Drugs. 2000;59(2):253–60;discussion 261–2, http://dx.doi.org/10.2165/00003495-200059020-00009.
51. Niafar M, Nakhjavani M. Efficacy and Safety of Insulin Glargine in Type 2Diabetic Patients with Renal Failure. J Diabetes Metab. 2012;03(04):2-5,http://dx.doi.org/10.4172/2155-6156.1000189.
52. JonesMC, Patel M. Insulin detemir: a long-acting insulin product. AmJ HealthSyst Pharm. 2006;63(24):2466-72, http://dx.doi.org/10.2146/ajhp060102.
53. Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, Luzio S, et al.Comparison of pharmacokinetics and dynamics of the long-acting insulinanalogs glargine and detemir at steady state in type 1 diabetes: a doubleblind,randomized, crossover study. Diabetes Care. 2007;30(10):2447-52,http://dx.doi.org/10.2337/dc07-0002.
54. Kiss I, Arold G, Roepstorff C, Bøttcher SG, Klim S, Haahr H. Insulindegludec: pharmacokinetics in patients with renal impairment. ClinPharmacokinet. 2014;53(2):175-83, http://dx.doi.org/10.1007/s40262-013-0113-2.
55. Bode BW. Use of rapid-acting insulin analogues in the treatment ofpatients with type 1 and type 2 diabetes mellitus: insulin pump therapyversus multiple daily injections. Clin Ther. 2007;29 Suppl D:S135-44.
56. Ruggenenti P, Flores C, Aros C, Ene-Iordache B, Trevisan R, Ottomano C,et al. Renal and metabolic effects of insulin lispro in type 2 diabeticsubjects with overt nephropathy. Diabetes Care. 2003;26(2):502-9, http://dx.doi.org/10.2337/diacare.26.2.502.
57. Ersoy A, Ersoy C, Altinay T. Insulin analogue usage in a haemodialysispatient with type 2 diabetes mellitus. Nephrol Dial Transplant. 2006;21(2):553-4, http://dx.doi.org/10.1093/ndt/gfi205.
58. Czock D, Aisenpreis U, Rasche FM, Jehle PM. Pharmacokinetics and pharmacodynamicsof lispro-insulin in hemodialysis patients with diabetesmellitus. Int J Clin Pharmacol Ther. 2003;41(10):492-7, http://dx.doi.org/10.5414/CPP41492.
59. Urata H, Mori K, Emoto M, Yamazaki Y, Motoyama K, Morioka T, et al.Advantage of insulin glulisine over regular insulin in patients with type 2diabetes and severe renal insufficiency. J Ren Nutr. 2015;25(2):129-34,http://dx.doi.org/10.1053/j.jrn.2014.07.011.
60. Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart inobesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol.2005;60(5):469-76, http://dx.doi.org/10.1111/j.1365-2125.2005.02476.x.
61. Baldwin D, Zander J, Munoz C, Raghu P, DeLange-Hudec S, Lee H, et al.A randomized trial of two weight-based doses of insulin glargine and glulisinein hospitalized subjects with type 2 diabetes and renal insufficiency.Diabetes Care. 2012;35(10):1970-4, http://dx.doi.org/10.2337/dc12-0578.
62. Thomas MC. Glycemic exposure, glycemic control, and metabolic karmain diabetic complications. Adv Chronic Kidney Dis. 2014;21(3):311-7,http://dx.doi.org/10.1053/j.ackd.2014.03.004.
63. Oh SW, Lee HJ, Chin HJ, Hwang JI. Adherence to clinical practiceguidelines and outcomes in diabetic patients. Int J Qual Health Care.2011;23(4):413-9, http://dx.doi.org/10.1093/intqhc/mzr036.
64. Triplitt C. Improving treatment success rates for type 2 diabetes: recommendationsfor a changing environment. Am J Manag Care. 2010;16(7 Suppl):S195-200.
65. Bailey RA, Wang Y, Zhu V, Rupnow MFT. Chronic kidney disease in USadults with type 2 diabetes: an updated national estimate of prevalencebased on Kidney Disease: Improving Global Outcomes (KDIGO) staging.BMC Res Notes. 2014;7:415, http://dx.doi.org/10.1186/1756-0500-7-415.
66. Slinin Y, Ishani A, Rector T, Fitzgerald P, MacDonald R, Tacklind J, et al.Management of hyperglycemia, dyslipidemia, and albuminuria inpatients with diabetes and CKD: a systematic review for a KDOQI clinicalpractice guideline. Am J Kidney Dis. 2012;60(5):747-69, http://dx.doi.org/10.1053/j.ajkd.2012.07.017.
67. Cefalu WT. Diabetes Care: "state of the union." Diabetes Care. 2012;36(1):1-3, http://dx.doi.org/10.2337/dc12-2182.
68. Ramirez SPB, McCullough KP, Thumma JR, Nelson RG, Morgenstern H,Gillespie BW, et al. Hemoglobin A(1c) levels and mortality in the diabetichemodialysis population: findings from the Dialysis Outcomes andPractice Patterns Study (DOPPS). Diabetes Care. 2012;35(12):2527-32,http://dx.doi.org/10.2337/dc12-0573.
69. Rhee CM, Leung AM, Kovesdy CP, Lynch KE, Brent GA, Kalantar-Zadeh K.Updates on the management of diabetes in dialysis patients. Semin Dial.2014;27(2):135-45, http://dx.doi.org/10.1111/sdi.12198.
70. Himmelfarb J, Tuttle KR. New therapies for diabetic kidney disease. N Engl JMed. 2013;369(26):2549-50, http://dx.doi.org/10.1056/NEJMe1313104.